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ABSTRACT
Homes are being built to be more airtight because of
demands for energy conservation in recent years. At
the same time, recognition of numerous sources of
formaldehyde in indoor environments has increased
concerns about health hazards from this pollutant.
Formaldehyde has been shown to cause and exacer-
bate asthmatic symptoms. In addition, the effects of
formaldehyde on the airway are proportional to the
concentration and duration of exposure and are
greater in inflamed than in healthy airways.
Formaldehyde may induce features of airway inflam-
mation associated with asthma, such as epithelial
disruption, microvascular leakage and increased
airway secretions. Exposure to this chemical may facil-
itate IgE sensitization to a variety of allergens, as well
as producing IgE-mediated allergic responses to itself.
Thus, avoidance of formaldehyde exposure may
reduce the incidence and severity of asthma, although
the ability of low concentrations of formaldehyde to
trigger mechanisms contributing to asthmatic symp-
toms is still debated. Setting appropriate exposure
limits for formaldehyde as an indoor environmental
pollutant requires further quantitative and predictive
evaluation of its health effects.
Key words: airway inflammation, asthma, formalde-
hyde, IgE, immune system, indoor environments.
INTRODUCTION
Formaldehyde, a known cause of occupational asthma,
may also adversely influence health when present in ordi-
nary room air. Formaldehyde has been found to be
related to ‘sick building syndrome’ (health disturbances
induced by chemical contaminants in office environ-
ments), which has shown an increased rate of occurrence
in Europe and North America following the first world oil
crisis.1 In recent years, the structure of housing in Japan
has rapidly shifted to Western forms and people now are
living in very airtight rooms during most of their daily 
routines. When room ventilation is inadequate, contami-
nants, including formaldehyde, may stagnate in rooms
and adversely affect the health of inhabitants. Allergic
diseases are increasing in occurrence and ‘sick house
syndrome’ has received attention as a household
counterpart of sick building syndrome.
Formaldehyde, a gaseous organic compound, is
soluble in water. It has strong reducing properties and is
chemically able to copolymerize various substances.
Such properties have made it a popular raw material in
the manufacture of urea-type or phenol-type synthetic
resins, both of which are used frequently as adhesive
agents in fabricating plywood, flooring, particle board
and fiberboard. Urea formaldehyde resin also is used in
textile synthesis for clothing, as a preservative in paper
and as a foam-type heat insulator. Furthermore,
formaldehyde is often added to products, such as wall-
paper, adhesive agents, cosmetics and detergents, as a
preservative or fungicide. When the ambient temperature
is increased, the formaldehyde contained in these pro-
ducts is volatilized and formaldehyde compounds are
decomposed to liberate formaldehyde, which is released
into room air. Cigarette smoke and combustion exhaust
gas also contain formaldehyde in high concentrations
and indoor formaldehyde concentrations often reach
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levels several-fold greater than those present in outdoor
environments.2 We often are exposed to relatively high
concentrations of formaldehyde gas in newly built
housing and in poorly ventilated clothing or furniture
stores. The formaldehyde contained in cosmetics, deter-
gents and sometimes wallpaper also comes into direct
contact with skin. Even most vaccine preparations
contain some formaldehyde, which is introduced sub-
cutaneously.
At monthly intervals over 2 years, Kodama et al.3 fol-
lowed changes in formaldehyde concentration within a
newly built single-family house of steel structure unit
design. Measurements were made in four places (living
room, bedroom, children’s room and bathroom) and
were averaged (Fig. 1). The average formaldehyde 
concentration before the occupants moved into the
house was 0.712 p.p.m. (highest in the bedroom,
1.175 p.p.m.). After the family moved in, average values
decreased, but they increased again in summer.
Thereafter, the formaldehyde concentrations decreased
only slightly and slowly. The formaldehyde concentration
1 year after moving in was more than 0.1 p.p.m., declin-
ing to less than 0.1 p.p.m. only after 2 years. A
concentration of 0.08 p.p.m. is the maximum allowable
indoor formaldehyde concentration, recommended by
the World Health Organization (WHO). The serial 
measurements above indicate that formaldehyde con-
tamination in the room air of Japanese housing is a very
serious problem.
RESPIRATORY HEALTH EFFECTS OF FORMALDEHYDE
Acute health effects of formaldehyde at 
various concentrations
Ambient formaldehyde primarily affects the upper airway
and eyes. Even in low-level exposure, people with height-
ened olfactory awareness may notice a foul odor, while
incurring no physiologic consequences. The odor thres-
hold for formaldehyde has been reported to vary between
0.05 and 1 p.p.m.1 Acute upper airway and eye irritation
are the most common complaints in homes and offices
where materials containing formaldehyde compounds
are used extensively. The degree of irritation is directly
proportional to the concentration and duration of
formaldehyde exposure. These symptoms appear to 
have a wide range of threshold concentrations (eye 
irritation, 0.01–2.0 p.p.m.; upper airway irritation,
0.1–25 p.p.m.).1 The US Industrial Health Foundation
panel,4 charged with recommending occupational expo-
sure limits, concluded from well-controlled studies of
volunteers that for most people, eye irritation unequivo-
cally due to formaldehyde does not occur below 1 p.p.m.
and that for most people moderate to severe eye, nose
and throat irritation does not occur until airborne con-
centrations exceed 2–3 p.p.m.
Uptake of formaldehyde by nasal mucous membranes
has been demonstrated to be extremely high,5 reflecting
the high water solubility of formaldehyde. This suggests
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Fig. 1 Changes in formalde-
hyde concentration within a
newly built single-family house
of steel structure unit design,
before and after the family has
moved in. Measurements were
made in four places (living
room, bedroom, children’s
room, and bathroom) and aver-
aged. Values are the mean
±SD.
that little formaldehyde should reach the lower airways
following nasal inhalation. However, lower airway and
pulmonary effects, such as cough, chest tightness and
dyspnea, have been observed at concentrations between
5 and 30 p.p.m.1 Levels of formaldehyde exceeding
50 p.p.m. can induce severe pulmonary edema and
inflammation.1 Relatively large amounts of the gas may
reach the lower airways via the mouth, followed by
almost complete uptake.5
Formaldehyde and occupational asthma
Occupational ‘formalin asthma’, a term referring to a
volatile aqueous formaldehyde solution, has been
described in a worker in a match factory6 and in workers
employed in the tanning and rubber industries.7 The
match factory report is the earliest reference to asthma
attributable to formaldehyde. In the other report, 28–48
workers who had been exposed to a variety of chemicals,
including formaldehyde, were suspected to have occupa-
tional asthma or asthmatic bronchitis.7 One person
showed immediate and delayed bronchoconstriction to
formaldehyde in a provocative test. Unfortunately, the
possible involvement of other chemicals in causing asth-
matic symptoms was not investigated. In addition, the
concentrations of formaldehyde used for the bronchial
challenge test were not recorded.
Hendrick and Lane have found that formaldehyde
caused a significant fall in the forced expiratory volume in
1 s (FEV1) in a hemodialysis nurse with asthma 2–6 h
after exposure in a provocative test.8 The decrease in
FEV1 was abolished by pretreatment with inhaled
betamethasone and the nurse’s asthmatic symptoms
were prevented by avoidance of unnecessary exposure to
formaldehyde. Another case in this report involved an
elderly pathologist with a 17 year history of working with
formaldehyde, who thought that his prolonged exposure
had worsened his asthmatic symptoms.8 Unexpectedly, a
formaldehyde provocative test was negative. The same
authors have reported similarly mixed results in a slightly
broader survey: two of five patients with asthma attribut-
able to formaldehyde (four staff members of a
hemodialysis unit and a patient undergoing hemodialy-
sis) had positive provocative tests with formaldehyde.9 A
significant fall in peak expiratory flow (PEF) also was
observed from 2 to several hours after challenge.
Subsequently, Hendrick and colleagues have observed
that bronchial hyperresponsiveness to formaldehyde in
the previously reported hemodialysis nurse8 persisted for
6 years, due to low levels of intermittent exposure.10 Thus,
repeatedly inhaling formaldehyde may prevent full recov-
ery from bronchial hyperresponsiveness and asthmatic
symptoms due to this agent. However, mechanisms
underlying the abnormal airway responses have not been
explained.
Nordman et al. administered a provocative test with
formaldehyde (1–2 p.p.m., 30 min) to 230 workers who
had been exposed to formaldehyde previously and mani-
fested asthmatic symptoms.11 Formaldehyde significantly
reduced PEF in 12 subjects (5.2%): immediate PEF
changes were observed in six cases, late PEF changes in
four and both immediate and late PEF changes in two.
Interestingly, these subjects with bronchial hyperrespon-
siveness to formaldehyde did not always show bronchial
hyperresponsiveness to histamine or methacholine, in
contrast to a report by Burge et al.,12 which has noted a
close relationship between histamine and formaldehyde
bronchial reactivity. The concentrations of formaldehyde
used in the provocative tests were as low as those
detected in domestic settings, suggesting that domestic
exposure may provoke, worsen or prolong asthmatic
symptoms in patients sensitive to formaldehyde. In the
study by Nordman et al., challenges were unblinded and
a positive response was defined as a 15% decrease in
PEF, measured with a Wright peak flowmeter. Therefore,
the conclusions may not be firm.
Frigas et al.13 have concluded that cases of formaldehyde-
induced asthma may be rare, in a study of formaldehyde
bronchial challenge (0.1–3 p.p.m., 20 min) that failed to
provoke bronchoconstriction in 13 selected patients with
symptoms suggestive of asthma, with suspected exposure
to formaldehyde as a cause. In contrast, the same
workers have found that one subject with asthma had
bronchial constriction as a result of exposure to urea-
formaldehyde foam, but not to formaldehyde gas.14
Airborne particles containing formaldehyde, then, may
contribute more to asthma symptoms than gaseous
formaldehyde. Krakowiak et al.15 have found that inhaled
formaldehyde at low doses (0.4 p.p.m. for 2 h) may have
no bronchoconstricting effect in asthmatic patients occu-
pationally exposed to formaldehyde or in healthy subjects,
although some transient symptoms of rhinitis occurred in
both groups at such doses. Moreover, no formaldehyde-
specific IgE antibodies were detected in serum from any
subject in that study.
Most clinical studies have found a low incidence of
positive provocative tests with formaldehyde, even in
patients whose asthmatic symptoms were attributable to
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formaldehyde. Thus, formaldehyde may not be an impor-
tant cause of asthma, because a positive provocative test
is essential to this determination. Further, inhaled
formaldehyde is unlikely to be potent in directly inducing
bronchoconstriction, because cigarette smoke, known to
contain 30–40 p.p.m. formaldehyde in side-stream sam-
pling, is not a common cause of acute airway
obstruction.16 In a few cases, bronchial exposure to
formaldehyde has produced sustained bronchoconstric-
tion several hours later; the reaction is reduced by
pretreatment with corticosteroids.8,9,11 This means that
formaldehyde can cause airway inflammation leading to
airflow limitation in specific populations. As described in
previous studies,11,13,15 clinical histories suggest that
chronic workplace exposure to formaldehyde is closely
related to asthmatic symptoms in many cases, even
though the prevalence of a positive provocative test with
formaldehyde is very low. This inconsistency suggests that
formaldehyde may exacerbate asthma or increase sus-
ceptibility to it, rather than typically acting as a direct
cause. Importantly, standardized methods for provocative
tests with formaldehyde have not been established.17,18
Therefore, conclusive evidence determining the role of
formaldehyde in development of asthma is still required.
Formaldehyde and pulmonary function in
healthy subjects
Alexandersson et al. have shown that small exposures to
formaldehyde (e.g. 0.36 p.p.m. for several hours) cause
slight but significant deterioration in lung function,
including a 2% decrease in the percentage FEV1 in 
non-asthmatic subjects occupationally exposed to
formaldehyde.19 The deterioration was reversible and no
lasting effects could be established. Both smokers and
non-smokers displayed similar changes. Kriebel et al.20
examined the effects on PEF change in 24 students
repeatedly exposed to formaldehyde (0.49–0.93 p.p.m.
for 3 h/week) during a clinical anatomy laboratory
course lasting 10 weeks. Peak expiratory flow measured
before each laboratory session declined over the semes-
ter by an average of 2% of baseline; the change was
statistically significant. In this study, asthma was among
the important predictors of PEF decrements. After 14
weeks away from the laboratory, the students’ PEF had
returned to pre-exposure levels. Kilburn et al. have
studied the effects of long-term workplace exposure to
low concentrations of formaldehyde on pulmonary func-
tion parameters (forced vital capacity and FEV1), in 280
non-smoking white women working as histologic techni-
cians.21 Most of this cohort exposed to formaldehyde had
better pulmonary function at the age of 20 than a com-
parison population at age of 20, but they had greater
decrements with time, resulting in lower pulmonary func-
tion values than in controls at the age of 60.
Formaldehyde in non-occupational settings
and symptoms of asthma
Krzyzanowski et al.22 have studied relationships of
chronic respiratory symptoms and pulmonary function to
formaldehyde in homes in a sample of 298 children and
613 adults. In the children, medically diagnosed asthma
and chronic bronchitis were more prevalent in houses
with higher formaldehyde levels (0.06–0.12 p.p.m.). In
addition, PEF values decreased linearly with increasing
concentration of formaldehyde, an effect discernibly
greater in asthmatic children than in healthy ones when
the ambient formaldehyde concentrations were below
0.05 p.p.m. Such relationships were not clearly evident
in adults. Smedje et al.23 have studied the physical char-
acteristics of school environments in terms of asthma,
finding concentrations of formaldehyde to be significantly
related to prevalence of childhood asthma.
These summarized studies suggest that, even in non-
asthmatic subjects, repeated and long-term exposure to
formaldehyde causes a small degree of bronchial
obstruction that probably results from airway inflamma-
tion. The changes appear to be proportional to the
ambient concentration and duration of exposure and are
greater in inflamed than in healthy airways. Furthermore,
long-term exposure to formaldehyde may cause irre-
versible lung dysfunction, although the decreases in
pulmonary function following single or repeated
formaldehyde exposures appear to be reversible.
Formaldehyde as an immunogen
Formaldehyde is a potent contact sensitizer that can elicit
contact dermatitis. As mentioned earlier, formaldehyde
has been demonstrated to induce bronchoconstriction
immediately following its inhalation in a small subgroup
of patients with asthma. The mechanisms underlying this
asthmatic response may be complicated. Inhaled
formaldehyde is presumed to rapidly combine with a
variety of proteins, such as albumin, inducing formalde-
hyde-specific IgE antibodies. These IgE, in turn, could
mediate bronchoconstriction.
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In the past, hemodialysis frequently exposed patients to
high levels of formaldehyde because of its use as a coil
disinfectant. Under those conditions, a patient may have
been infused with as much as 126 mg formaldehyde
during a single hemodialysis session.18 Maurice et al.
have reported a 20-year-old woman undergoing long-
term hemodialysis who developed severe anaphylactic
shock, requiring resuscitation, within 20 min of beginning
a session.24 Skin prick tests with 0.1% and 1% formalin
were positive in the patient but negative in control sub-
jects. Levels of formaldehyde-specific IgE antibodies were
elevated in a radioallergosorbent test (RAST) using paper
discs coated with formaldehyde-conjugated human serum
albumin (formaldehyde-HSA). Similarly, Ebner and Kraft25
and Wantke et al.26 have reported that four patients under-
going dental treatment with formaldehyde-containing
tooth-filling material developed systemic reactions 1–10 h
later. These patients had a positive RAST to formaldehyde-
HSA but a negative skin test with 1% formalin, suggesting
the involvement of IgE-mediated mechanisms. Patterson
et al.27 have reported that IgG antibodies to formalde-
hyde-HSA were more prevalent in subjects who had been
exposed to formaldehyde intravenously during hemodial-
ysis using formaldehyde-disinfected equipment than in
32 persons exposed to gaseous formaldehyde; only one
subject with gaseous exposure had IgG antibodies to
formaldehyde-HSA. Systemic exposure to significant
levels of circulating formaldehyde, then, frequently results
in both IgE and IgG sensitization.
Wilhelmsson and Holmstrom have reported that two of
30 formaldehyde-exposed workers with rhinitis possessed
high levels of IgE antibodies to formaldehyde-HSA, as
determined by RAST.28 The two workers had severe rhini-
tis, strongly linked by clinical evidence to the workplace.
This observation indicates that long-term inhalation of
formaldehyde can sensitize atopic individuals. However,
whether formaldehyde-specific IgE antibodies contributed
to the symptoms of rhinitis in these workers was not deter-
mined by provocative testing. Grammer et al.29 have
described a worker with clinical symptoms compatible
with bronchospasm induced by inhaled formaldehyde.
This individual had significant levels of IgE and IgG anti-
bodies to formaldehyde-HSA and a positive skin test to
formaldehyde-HSA, although a provocative test with
formaldehyde at 0.3–5 p.p.m. for 20 min was negative.
Grammer et al. carried out a more extensive clinical and
immunologic evaluation of 37 workers exposed to
formaldehyde.30 While none had IgE or IgG antibodies 
to formaldehyde-HSA, some complained of irritant 
symptoms related to workplace exposure to formalde-
hyde or other irritant chemicals. When Salkie examined
the prevalence of atopic symptoms and hypersensitivity to
formaldehyde in 63 pathologists in active practice, 
29 complained of formaldehyde hypersensitivity, but
formaldehyde-specific IgE antibodies were not
detected.31 Kramps et al. have reported a similar nega-
tive result, finding formaldehyde-specific IgE antibodies
in only one of 86 sera from individuals exposed to
formaldehyde.32 Liden et al. have found that among 23
patients with a previous positive patch-test reaction to
formaldehyde, only two had formaldehyde-specific IgE
antibodies.33 Wantke et al. assessed the sensitizing
potency of formaldehyde exposure during 4 weeks of an
anatomy dissection course in 45 medical students.34 A
4 week exposure to low concentrations of gaseous
formaldehyde (0.059–0.219 p.p.m.) did not induce pro-
duction of IgE reactive to formaldehyde. However,
Wantke et al. have reported elevated IgE levels to
formaldehyde in 24 of 62 8-year-old children (39%)
attending a primary school where indoor formaldehyde
concentrations did not exceed 0.08 p.p.m.35 Therefore,
children may be more susceptible to IgE sensitization to
formaldehyde than adults. In this study of children,
however, IgE sensitization did not correlate with clinical
complaints. In contrast, there was a high correlation
between the prevalence of symptoms such as rhinitis,
cough and epistaxis and formaldehyde concentrations in
the classrooms.
Collectively, the results suggest that inhaled formalde-
hyde appears to have little ability to produce IgE
sensitization in adults, although children may be more
sensitive to formaldehyde in this respect. In addition, the
presence of formaldehyde-specific IgE antibodies is not
necessarily associated with clinical symptoms. To date, no
definite evidence has shown that gaseous formaldehyde
induces IgE-dependent bronchoconstriction.
Formaldehyde as a modulator of antibody
production in animal experiments
Tarkowski and Gorski have investigated the effect of
formaldehyde exposure on IgE sensitization to ovalbumin
in mice.36 Significant enhancement of IgE antibodies to
ovalbumin has been observed in mice exposed to
formaldehyde at 1.6 p.p.m. (6 h/day) for 10 days and
sensitized to ovalbumin intranasally. However, the same
treatment with formaldehyde had no facilitating effect on
IgE sensitization to intraperitoneally injected ovalbumin.
INDOOR FORMALDEHYDE AND THE AIRWAY 155
In guinea-pigs, Riedel et al.37 have demonstrated that
short-term exposure to low concentrations of formalde-
hyde (e.g. 0.25 p.p.m.) significantly enhances the
production of IgG1 antibodies to ovalbumin as well; the
effect is dependent on formaldehyde concentrations. The
results suggest that inhaled formaldehyde may facilitate
IgE sensitization to a variety of inhalant allergens, thus
increasing the prevalence of asthmatic symptoms.
However, mechanisms underlying these immunologic
effects remain unclear.
Formaldehyde as a trigger of asthma-like
states in animal experiments
Asthma is a chronic inflammatory disease of the airway
with immunohistopathologic features including denuda-
tion of airway epithelium, collagen deposition beneath
basement membranes, edema, mast cell activation and
eosinophil, neutrophil and T-lymphocyte infiltration.38 A
trigger of asthma is defined as a risk factor that exacer-
bates a variety of inflammatory processes in the airway,
leading to recurrent bronchial obstruction. As mentioned
earlier, several clinical studies have suggested that
formaldehyde may trigger asthma, but the mechanisms
involved are not clear.
We have investigated the effect of gaseous formaldehyde
on airway microvascular leakage and bronchoconstriction
in mechanically ventilated rats.39 To examine the role 
of formaldehyde-induced tachykinin release, the effect 
of a selective inhibitor of tachykinin NK1 receptors 
(CP-99 994) has been studied on airway responses
induced by formaldehyde. Inhalation of gaseous
formaldehyde produces a concentration-dependent
increase in vascular permeability in the rat trachea and
main bronchi (Fig. 2), but no bronchoconstrictor effect is
observed. Wei and Kiang40 have previously found that an
extremely high concentration of formalin vapor (approxi-
mately 594 p.p.m.) induces tracheal microvascular
leakage in anesthetized rats, but we have noted that a
much lower threshold concentration (> 2 p.p.m.) can
induce some increase above baseline levels of leakage 
in the airways. Formaldehyde concentrations above
2 p.p.m. are sometimes detected in occupational settings.
The CP-99 994 completely abolishes formaldehyde-
induced airway microvascular leakage (Fig. 3), indicating
that inhaled formaldehyde can release tachykinins, such
as substance P, from airway sensory nerve endings in the
same way as capsaicin. Because ketotifen (a selective H1
receptor antagonist) and HOE140 (a selective bradykinin
B2 receptor antagonist) have no effect on airway
microvascular leakage induced by formaldehyde, activa-
tion of bradykinin receptors and mast cells does not
appear to participate importantly in this airway response.
In our rat model, formaldehyde significantly increases
serum albumin exudation into the airway lumen in a 
concentration-dependent fashion, with a threshold con-
centration of 2–5 p.p.m. (Fig. 4). The airway response is
abolished completely by the tachykinin NK1 receptor
antagonist CP-99 994. Hastie et al. have demonstrated
that formaldehyde directly inhibits ciliary activity in airway
epithelium and that this effect is not mediated by altered
rheologic properties of mucus.41 The ciliary dysfunction
elicited by formaldehyde was reversible. Nevertheless,
temporary reduction of ciliary function would supposedly
increase the dose of solubilized formaldehyde through
lack of clearance and thereby increase the likelihood of
locally cytotoxic levels. Cellular changes associated with
exposure to formaldehyde include not only alterations of
cilia, but also hypertrophy of the goblet cells.42 Together,
these changes may lead to the formation of inspissated
mucus plugs. In these varied ways, airway tissue
responses induced by formaldehyde may contribute to
airflow limitation, resulting in asthma.
Swiecichowski et al. have reported that in the guinea-
pig, hyperresponsiveness to intravenous acetylcholine
can be induced by lower formaldehyde concentrations
(> 0.3 p.p.m.) when the duration of exposure is
extended from 2 to 8 h.43 Formaldehyde has also been
found to heighten airway smooth muscle responsiveness
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Fig. 2 Evans blue dye extravasation in the (a) trachea and (b)
main bronchi induced by 10 min inhalation of gaseous
formaldehyde (j) or room air (h). Values are the mean
±SEM (n = 5–7). *P < 0.05 and †P < 0.01 compared with
the room air-exposed group.
to acetylcholine and carbachol ex vivo. In the guinea-pig
study, bronchoconstriction was also observed after
inhalation of formaldehyde at levels above 3 p.p.m. for
2 h,43 in contrast to our previous results in rats.39 We have
found in further studies in rats (Sakamoto et al., unpubl.
data, 1998) that formaldehyde induces neutrophil influx
into the airway and epithelial denudation within 60 min
of inhalation (15 p.p.m., 10 min). The tachykinin NK1
antagonist CP-99 994 completely blocks migration of
neutrophils, but has no effect on epithelial denudation.
Formaldehyde may attract neutrophils into the airway by
tachykinin NK1 receptor-mediated mechanisms, as cap-
saicin does.44 Epithelial denudation, in contrast, may
result from the non-specific cytotoxity of formaldehyde.
Neutrophils can participate in inflammatory responses,
including airway epithelial disruption, by releasing chem-
ical mediators, superoxide anions or proteases. In
extensively disrupted epithelium, neurogenic inflamma-
tion appears to be exaggerated;45 the surface of intact
epithelium is rich in neutral endopeptidases that degrade
tachykinins and bradykinin. Such changes of epithelium
may be associated with hyperresponsiveness to a wide
variety of stimuli. Airway hyperresponsiveness is impor-
tant to the pathogenesis of asthma and usually correlates
with clinical severity.
Long-term exposure to formaldehyde may cause irre-
versible airflow limitation in human airways. However, no
previous animal study has demonstrated toxicity from
prolonged exposure to formaldehyde in the lower airway.
Rusch et al.46 have conducted a 26 week inhalation study
in monkeys, rats and hamsters. The animals were
exposed continuously to formaldehyde at concentrations
of 0.19, 0.98 and 2.95 p.p.m. for 22 h/day. The results
showed induction of nasal lesions only in rats and
monkeys exposed to 2.95 p.p.m. formaldehyde, which
induced squamous metaplasia in 62% of animals. No
lower respiratory tract effects were observed, even at
2.95 p.p.m. formaldehyde. Holmstrom et al.47 have
examined histologic changes in the nasal mucosa of 
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Fig. 3 Effect of CP-99 994,
HOE140 and ketotifen on Evans
blue dye extravasation in the (a)
trachea and (b) main bronchi
induced by inhalation of gaseous
formaldehyde (15 p.p.m. for 
10 min). Rats were treated with 3
or 6 mg/kg i.v. CP-99 994 (h),
0.65 mg/kg i.v. HOE140 ( ),
1 mg/kg i.v. ketotifen ( ) or the
vehicle only (0.5 mL/kg i.v. 0.9%
saline; j) before formaldehyde
challenge. Sham, animals ex-
posed to room air for 10 min
after pretreatment with 0.9%
saline (0.5 mL/kg i.v.). Data 
are the mean ± SEM (n = 6–7).
*P < 0.05 compared with the
sham treatment. †P < 0.01 com-
pared with the control treatment.
Fig. 4 Amount of Evans blue dye that exuded into the
tracheo-bronchial lumen after 10 min inhalation of gaseous
formaldehyde or room air. The dye in the tracheo-bronchial
lumen was absorbed on filter paper (7 · 30 mm). Sham,
animals exposed to room air for 10 min. Values are the mean
± SEM (n = 6). *P < 0.05 compared with sham treatment.
rats following long-term exposure to formaldehyde
(12.4 p.p.m.) and wood dust (25 mg/m3). One of 16
rats had developed nasal squamous cell carcinoma at
104 weeks of exposure. In contrast, epidemiologic data
regarding the human carcinogenicity of formaldehyde
are variable and definitive conclusions cannot be
reached.1
CONCLUSION
Previous studies of occupational asthma associated with
formaldehyde have reported that the chemical exposure
is chronologically related to onset or exacerbation of
asthmatic symptoms in many cases; however, it is very
rare that the result of provocative formaldehyde inhala-
tion test is positive. This difference may be attributed to
multiple factors. First, direct effects of formaldehyde on
airway contraction are relatively slight, but formaldehyde
may still have other potent effects causing dysfunction or
inflammation in airways. Second, additional chemical
contaminants are present in the air in workplaces and
homes. Formaldehyde may be related to onset and exac-
erbation of asthmatic symptoms in the specific context of
such composite contamination. Third, water drops or
particulates containing formaldehyde entering the airway
may bring about airway reactions specific to non-
gaseous formaldehyde. These issues are important
targets for future investigation.
Long-term and repeated exposure to formaldehyde
may influence pulmonary function. Because infants
spend most of their time in indoor environments, they are
particularly likely to be exposed to contaminants in room
air, making study of the influence of airborne formalde-
hyde on their airways an urgent priority. When children
are exposed to cigarette smoke or SO2 in infancy, their
pulmonary function may be decreased after several
years48,49 and exposure to formaldehyde in infancy simi-
larly may have effects on the health of children that are
still unknown.
The retention ratio of formaldehyde-specific IgE anti-
bodies has been found to be very low in patients
diagnosed with occupational asthma attributable to
formaldehyde. However, Wantke et al.35 have detected
formaldehyde-specific IgE antibody in 39% of school-
children, which suggests that children may have a more
marked immune reaction to formaldehyde than adults.
With regard to formaldehyde-specific IgE antibodies, if
allergic inflammation caused by formaldehyde is super-
imposed on conventional asthmatic airway dysfunction,
the effects of IgE sensitization by formaldehyde may be
very serious. However, convincing evidence has not been
found that patients with asthma who are positive for
formaldehyde-specific IgE antibodies are exceptionally
severely sick or refractory to treatment. Many of these
issues require future study.
Formaldehyde has been hypothesized to directly
produce dysfunction and inflammation in airways and
also to act indirectly as a factor promoting antibody pro-
duction and causing various types of inflammatory
reactions. Allowable standards for formaldehyde concen-
tration in air have been set at 0.5 p.p.m. for work
environments (recommended by WHO and the Japanese
Association for Industrial Hygiene) and 0.08 p.p.m. for
non-occupational indoor environments (WHO); these
standards may require revision as new data become
available. Above all and more generally, more ventilation
is needed in homes and building materials and interior
furnishings should be sought that generate smaller
amounts of formaldehyde and other volatile organic
gases.
REFERENCES
1 Samet JM, Marbury MC, Spengler JD. Health effects and
sources of indoor air pollution. Part II. Am. Rev. Respir. Dis.
1988; 137: 221–42.
2 Sakai K, Yamanaka K. Winter indoor concentrations of
formaldehyde and nitrogen dioxide in residences and
factors affecting them. Annu. Rep. Nagoya City Public
Health Res. Inst. 1996; 42: 52–7 (in Japanese).
3 Kodama Y, Matumura T, Kawamoto T et al. Investigation
for improving indoor air quality of domestic environments.
In: Annual report of The Pollution-related Health Damage
Compensation and Prevention Association of Japan.
Tokyo: Nihon Kankyoeisei Center, 1993; 233–93 (in
Japanese).
4 Paustenbach D, Alarie Y, Kulle T et al. A recommended
occupational exposure limit for formaldehyde based on
irritation. J. Toxicol. Environ. Health 1997; 50: 217–63.
5 Egle JL. Retention of inhaled formaldehyde, propionalde-
hyde, and acrolein in the dog. Arch. Environ. Health 1972;
25: 119–24.
6 Vaughn WT. The practice of allergy. St Louis: CV Mosby,
1939.
7 Popa V, Teculescu D, Stanescu D, Gavrilescu N. Bronchial
asthma and asthmatic bronchitis determined by simple
chemicals. Dis. Chest 1969; 56: 395–404.
8 Hendrick DJ, Lane DJ. Formalin asthma in hospital staff.
BMJ 1975; 15: 607–8.
9 Hendrick DJ, Lane DJ. Occupational formalin asthma. Br.
J. Ind. Med. 1977; 34: 11–18.
10 Hendrick DJ, Rando RJ, Lane DJ, Morris MJ. Formaldehyde
158 T SAKAMOTO ET AL.
asthma: Challenge exposure levels and fate after five
years. J. Occup. Med. 1982; 24: 893–7.
11 Nordman H, Keskinen H, Tuppurainen M. Formaldehyde
asthma – rare or overlooked? J. Allergy Clin. Immunol.
1985; 75: 91–9.
12 Burge PS, Harries MG, Lam WK, O’Brien IM, Patchett PA.
Occupational asthma due to formaldehyde. Thorax 1985;
40: 255–60.
13 Frigas E, Filley WV, Reed CE. Bronchial challenge with
formaldehyde gas: Lack of bronchoconstriction in 13
patients suspected of having formaldehyde-induced
asthma. Mayo Clin. Proc. 1984; 59: 295–9.
14 Frigas E, Filley WV, Reed CE. Asthma induced by dust from
urea-formaldehyde foam insulating material. Chest 1981;
79: 706–7.
15 Krakowiak A, Gorski P, Pazdrak K, Ruta U. Airway response
to formaldehyde inhalation in asthmatic subjects with sus-
pected respiratory formaldehyde sensitization. Am. J. Ind.
Med. 1998; 33: 274–81.
16 Higenbottam T, Feyeraband C, Clark TJH. Cigarette
smoke inhalation and the acute airway response. Thorax
1980; 35: 246–54.
17 Imbus HR. Clinical evaluation of patients with complaints
related to formaldehyde exposure. J. Allergy Clin.
Immunol. 1985; 76: 831–40.
18 Bardana EJ, Montanaro A. Formaldehyde: An analysis of
its respiratory, cutaneous, and immunologic effects. Ann.
Allergy 1991; 66: 441–52.
19 Alexandersson R, Hedenstierna G, Kolmodin-Hedman B.
Exposure to formaldehyde: Effects on pulmonary function.
Arch. Environ. Health 1982; 37: 279–83.
20 Kriebel D, Sama SR, Cocanour B. Reversible pulmonary
responses to formaldehyde. Am. Rev. Respir. Dis. 1993;
148: 1509–15.
21 Kilburn KH, Warshaw R, Thornton JC. Pulmonary function
in histology technicians compared with women from
Michigan: Effects of chronic low dose formaldehyde on a
national sample of women. Br. J. Ind. Med. 1989; 46:
468–72.
22 Krzyzanowski M, Quackenboss JJ, Lebowitz MD. Chronic
respiratory effects of indoor formaldehyde exposure.
Environ. Res. 1990; 152: 117–25.
23 Smedje G, Norback D, Edling C. Asthma among sec-
ondary schoolchildren in relation to the school
environment. Clin. Exp. Allergy 1997; 27: 1270–8.
24 Maurice F, Rivory J-P, Larsson PH, Johansson SGO,
Bousquet J. Anaphylactic shock caused by formaldehyde in
a patient undergoing long-term hemodialysis. J. Allergy
Clin. Immunol. 1986; 77: 594–7.
25 Ebner H, Kraft D. Formaldehyde-induced anaphylaxis after
dental treatment? Contact Dermatitis 1991; 24: 307–9.
26 Wantke F, Hemmer W, Haglmuller T, Gotz M, Jarisch R.
Anaphylaxis after dental treatment with a formaldehyde-
containing tooth-filling material. Allergy 1995; 50:
274–6.
27 Patterson R, Dykewicz MS, Evans R et al. IgG antibody
against formaldehyde human serum proteins: a compari-
son with other IgG antibodies against inhalant proteins
and reactive chemicals. J. Allergy Clin. Immunol. 1989;
84: 359–66.
28 Wilhelmsson B, Holmstrom M. Positive formaldehyde-RAST
after prolonged formaldehyde exposure by inhalation.
Lancet 1987; ii: 164.
29 Grammer LC, Harris KE, Cugell DW, Patterson R.
Evaluation of a worker with possible formaldehyde-
induced asthma. J. Allergy Clin. Immunol. 1993; 92:
29–33.
30 Grammer LC, Harris KE, Shaughnessy MA et al. Clinical
and immunologic evaluation of 37 workers exposed to
gaseous formaldehyde. J. Allergy Clin. Immunol. 1990;
86: 177–81.
31 Salkie ML. The prevalence of atopy and hypersensitivity to
formaldehyde in pathologists. Arch. Pathol. Lab. Med.
1991; 115: 614–16.
32 Kramps JA, Peltenburg LTC, Kerklaan PRM, Spieksma
FTHM, Valentijn RM, Dijkman JH. Measurement of specific
IgE antibodies in individuals exposed to formaldehyde.
Clin. Exp. Allergy 1989; 19: 509–14.
33 Liden S, Scheynius A, Fischer T, Johansson SGO, Ruhnek-
Forsbeck M, Stejskal V. Absence of specific IgE antibodies
in allergic contact sensitivity to formaldehyde. Allergy
1993; 48: 525–9.
34 Wantke F, Focke M, Hemmer W et al. Formaldehyde and
phenol exposure during an anatomy dissection course: 
A possible source of IgE-mediated sensitization? Allergy
1996; 51: 837–41.
35 Wantke F, Demmer CM, Tappler P, Gotz M, Jarisch R.
Exposure to gaseous formaldehyde induces IgE-mediated
sensitization to formaldehyde in schoolchildren. Clin. Exp.
Allergy 1996; 26: 276–80.
36 Tarkowski M, Gorski P. Increased IgE antiovalbumin level in
mice exposed to formaldehyde. Int. Arch. Allergy Immunol.
1995; 106: 422–4.
37 Riedel F, Hasenauer E, Barth PJ, Koziorowski A, Rieger
CHL. Formaldehyde exposure enhances inhalative allergic
sensitization in the guinea pig. Allergy 1996; 51: 94–9.
38 National Asthma Education and Prevention Program.
Expert panel report 2. Guidelines for the diagnosis and
management of asthma. Bethesda: National Heart, Lung
and Blood Institute, 1997.
39 Ito K, Sakamoto T, Hayashi Y et al. Role of tachykinin and
bradykinin receptors and mast cells in gaseous formalde-
hyde-induced airway microvascular leakage in rats. Eur. J.
Pharmacol. 1996; 307: 291–8.
40 Wei ET, Kiang JG. Inhibition of protein exudation from the
trachea by corticotropin-releasing factor. Eur. J. Pharmacol.
1987; 140: 63–7.
41 Hastie AT, Patrick H, Fish JE. Inhibition and recovery of
mammalian respiratory ciliary function after formalde-
hyde exposure. Toxicol. Appl. Pharmacol. 1990; 102:
282–91.
42 Monticello TM, Morgan KT, Everitt JI, Popp JA. Effects of
formaldehyde gas on the respiratory tract of rhesus
monkeys: Pathology and cell proliferation. Am. J. Pathol.
1989; 134: 515–27.
43 Swiecichowski AL, Long KJ, Miller ML, Leikauf GD.
INDOOR FORMALDEHYDE AND THE AIRWAY 159
Formaldehyde-induced airway hyperreactivity in vivo and
ex vivo in guinea pigs. Environ. Res. 1993; 61: 185–99.
44 Umeno E, Nadel JA, McDonald DM. Neurogenic inflam-
mation of the rat trachea: Fate of neutrophils that adhere
to venules. J. Appl. Physiol. 1990; 69: 2131–6.
45 Barnes PJ. Asthma as an axon reflex. Lancet 1986; i: 242–5.
46 Rusch GM, Clary JJ, Rinehart WE, Bolte HF. A 26-week
inhalation toxicity study with formaldehyde in the monkey,
rat, and hamster. Toxicol. Appl. Pharmacol. 1983; 68:
329–43.
47 Holmstrom M, Wilhelmsson B, Hellquist H. Histological
changes in the nasal mucosa in rats after long-term expo-
sure to formaldehyde and wood dust. Acta Otolaryngol.
1989; 108: 274–83.
48 Soyseth V, Kongerud K, Haarr D, Strand O, Bolle R, Boe J.
Relation of exposure to airway irritants in infancy to preva-
lence of bronchial hyperresponsiveness in schoolchildren.
Lancet 1995; 345: 217–20.
49 Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen
M, Morgan WJ. Asthma and wheezing in the first six years
of life. The Group Health Medical Associates. N. Engl. J.
Med. 1995; 332: 133–8.
160 T SAKAMOTO ET AL.
